Successful drug development requires a therapeutic regimen that is safe and maximally effective. Morpholino-mediated exon skipping has been demonstrated to achieve restoration of dystrophin in both animal models (mice and dogs) and in DMD boys in early clinical trials. In addition to efficacy, toxicity must be considered in optimizing dose selection for AO therapy. Experience with PMO-AO suggests that while these compounds have a better therapeutic index compared to other AO chemistries, renal effects are anticipated to be the primary dose limiting toxicity. Establishment of reliable and reproductive methods for pre-clinical and clinical monitoring of renal effects of morpholino AO is critical for optimal dose selection and a """"""""class"""""""" approval regulatory strategy. Preliminary GLP toxicology studies, and non-GLP studies using high dose morpholino AO directed at exon 51 (12 wk, 960 mg/kg/wk IV murine) showed significant accumulation of the drug in kidney proximal tubule cells. However, kidney accumulation resolved once drug treatment was stopped, suggesting optimized dosing could minimize renal toxicity or that a drug """"""""holiday"""""""" may be needed in the regimen. Here we hypothesize that establishing an appropriate therapeutic window in DMD patients will involve a balance of muscle retention of AO drug (efficacy) vs. kidney retention (toxicity). Therefore, the goal of this project is to systematically investigate the dosing schedules that achieve this balance through the following two aims.
Aim 1 will carry out 6 month chronic comparative dosing of morpholino drug in rats using iPRECIO telemetry pumps (jugular vein cannulation), with endpoints of urine and epithelial cell biochemistry (Core B), kidney histology and novel biomarkers (Project 2).
In Aim 2, we will carry out a similar IV dosing schedule in the mouse disease model (mdx), with the goal of testing drug efficacy, drug bioavailability in muscle (RT-PCR and dystrophin quantity), and kidney accumulation (Core B, and Project 2). This systematic comparison of multiple drugs in multiple species will provide an assessment of the optimized therapeutic Index. Use of morpholino AO to correct genetic defects is rapidly advancing to several other human diseases such as FSHD, Cystic fibrosis, myotonic dystrophy, LGMD etc. Therefore the efficacy and toxicity data generated from this proposal have much broader implications than treatment for Duchenne muscular dystrophy.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZHD1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Research Institute
United States
Zip Code
Yu, Qing; Morales, Melissa; Li, Ning et al. (2018) Skeletal, cardiac, and respiratory muscle function and histopathology in the P448Lneo- mouse model of FKRP-deficient muscular dystrophy. Skelet Muscle 8:13
Defour, Aurelia; Medikayala, Sushma; Van der Meulen, Jack H et al. (2017) Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle. Hum Mol Genet 26:1979-1991
Novak, James S; Hogarth, Marshall W; Boehler, Jessica F et al. (2017) Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle. Nat Commun 8:941
Smits, Anne; van den Anker, John N; Allegaert, Karel (2017) Clinical pharmacology of analgosedatives in neonates: ways to improve their safe and effective use. J Pharm Pharmacol 69:350-360
Vila, Maria C; Rayavarapu, Sree; Hogarth, Marshall W et al. (2017) Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy. Cell Death Differ 24:330-342
Hathout, Yetrib; Seol, Haeri; Han, Meng Hsuan J et al. (2016) Clinical utility of serum biomarkers in Duchenne muscular dystrophy. Clin Proteomics 13:9
Gupta, Charu; Massaro, An N; Ray, Patricio E (2016) A new approach to define acute kidney injury in term newborns with hypoxic ischemic encephalopathy. Pediatr Nephrol 31:1167-78
Hathout, Yetrib; Conklin, Laurie S; Seol, Haeri et al. (2016) Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children. Sci Rep 6:31727
Shoji, Kensuke; Bradley, John S; Reed, Michael D et al. (2016) Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms. Antimicrob Agents Chemother 60:2150-6
Allegaert, Karel; van den Anker, John N (2016) Neonatal withdrawal syndrome: reaching epidemic proportions across the globe. Arch Dis Child Fetal Neonatal Ed 101:F2-3

Showing the most recent 10 out of 59 publications